The text starts here.

News Release

FOR IMMEDIATE RELEASE
May 7, 2004

Amendment of the Co-Development, Licensing and Supply
Agreement for the Obesity Management Agent KES524

Eisai Co., Ltd. (Headquarters: Tokyo, President: Haruo Naito) and Abbott GmbH & Co., KG (Headquarters: Ludwigshafen, Germany, Managing Director:Dieter Wagner), formerly Knoll AG have signed a letter of agreement to amend the original co-development, licensing and supply agreement for KES524 (generic name: sibutramine) concluded in December 1997. Under the amendment, Eisai shall have the exclusive right and sole responsibility for the continued development and marketing of the product in Japan. The companies signed the binding amendment letter on April 27. KES524, an obesity management, is central acting serotonin and noradrenaline reuptake inhibitor.


The principal change from the former agreement is that the development, marketing and promotion of KES524 will be performed solely by Eisai instead of co-development and co-marketing by Eisai and Abbott Japan, a Japanese subsidiary of Abbott Laboratories.


Eisai will promote the development of KES524 more actively in order to contribute the obesity management that is of increasing social concern in recent years in Japan.



[The amended points in the contract and product profile are attached for reference.]


Contacts:

Eisai Co., Ltd.
Corporate Communications Department
81-3-3817-5120

[ Reference Data ]


Original agreement The Amended points as of April 30, 2004
Development and
Commercialization
Co-development and co-marketing by Eisai and Abbott Japan Development and commercialization exclusively by Eisai

[ Profile of KES524 ]
Generic Name : sibutramine
Intended Indication: Obesity Management
Mode of Action : Inhibition of noradrenalin and serotonin reuptake

Sibutramine inhibits the reuptake of neurotransmitters such as noradrenalin and serotonin, and enhances satiety (the feeling of fullness) and metabolic rate, resulting in a loss of body weight.
Formulation : Capsule
Origin : Abbott Laboratories
Clinical Stage : Phase II completed
Marketed Countries : More than 75 countries including the U.S. and Europe.